Key facts
- Notable investors include Frees Fund, Shunxin Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Baiyao Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Baiyao Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Baiyao Technology
Developer of an artificial intelligence and biopharmaceutical platform designed to realise life engineering through AI-driven virtual cell modelling. The company offers world-leading pre-trained large cell models, multi-omics fusion algorithms, and intelligent cell analysis platforms, enabling biomedical researchers and pharmaceutical developers to accelerate cell simulation, gene regulation studies, and precision drug discovery.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2024
- Website
- bio-compass.ai/
- Ownership
- Privately Held (backing)
Baiyao Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baiyao Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baiyao Technology in its N-PORT filings yet. We sweep new filings monthly.